Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future

Daniela Pugliese, Carla Felice, Alfredo Papa, Antonio Gasbarrini, Gian Lodovico Rapaccini, Luisa Guidi, Alessandro Armuzzi

Risultato della ricerca: Contributo in rivistaArticolo in rivista

31 Citazioni (Scopus)


INTRODUCTION: Anti TNF-α agents have become a significant advance in the management of ulcerative colitis, proving to induce, with rapid onset, clinical and endoscopic remission. However, there is still a considerable unmet medical need in ulcerative colitis. Areas covered: The aim of this review was to summarize the patterns of use and the effectiveness of anti TNF-α in ulcerative colitis, highlighting their current position in treatment algorithms. Moreover, we set out a five-year view hypothesizing different treatment strategies. Expert commentary: The rapid onset of action and the effectiveness in inducing mucosal healing are the most important pros of anti TNF-α, supporting present and future use. Conversely, the relevant risk of loss of response and the safety profile have raised several concerns. In the future, the advent of different molecular targeting therapies can improve the management of UC patients, evolving to individually tailored strategies.
Lingua originaleEnglish
pagine (da-a)1-11-11
RivistaExpert Review of Clinical Immunology
Stato di pubblicazionePubblicato - 2016


  • Ulcerative colitis
  • anti TNF-α
  • biosimilar
  • mucosal healing
  • remission
  • vedolizumab


Entra nei temi di ricerca di 'Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future'. Insieme formano una fingerprint unica.

Cita questo